Related Experiment Video
Updated: Mar 24, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors
José Yélamos1, Miguel Galindo2, Judith Navarro2
1Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Immunology, Hospital del Mar, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Abstract:
Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave β-NAD+ and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy.
Insights
Combining PARP inhibitors with monoclonal antibodies (mAbs) shows synergistic effects in cancer therapy. This approach enhances treatment efficacy beyond monotherapies, offering new hope for patients with limited clinical benefit.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) are effective cancer therapeutics, but limited efficacy and resistance necessitate combination strategies.
- Many patients do not achieve long-term clinical benefit from mAb monotherapy, highlighting the need for improved treatment approaches.
Approach:
- This review synthesizes recent data on the combination of Poly (ADP-ribose) polymerase (PARP) inhibitors and mAbs in cancer treatment.
- The discussion focuses on elucidating the molecular mechanisms underlying the observed synergistic therapeutic effects.
Key Points:
- PARP enzymes play a crucial role in DNA repair by cleaving β-NAD+.
- Combining PARP inhibitors with mAbs demonstrates synergistic therapeutic effects in preclinical and clinical cancer studies.
- Understanding the molecular interplay is key to optimizing combination therapies.
Conclusions:
- The combination of PARP inhibitors and mAbs represents a promising strategy to overcome resistance and enhance therapeutic outcomes in cancer.
- Further research into the synergistic mechanisms can guide the development of more effective cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...